On December 2, 2016, hosted by the Administration Committee of Pingshan New District of Shenzhen and Chinese Gene Sequencing Technology and Industry Alliance, organized by Shenzhen HYK Gene Technology Co., Ltd., the first "Summit of Chinese Gene Sequencing Technology and Industry Alliance & Opening Ceremony of the Alliance's Base in Shenzhen" was held grandly at Pingshan New District of Shenzhen. The event was attended by more than 250 famous experts and scholars of the industry, governmental leaders, excellent enterprise representatives, senior investment experts and media guests from home and abroad.

Venue of the Summit

Dr. Sheng Sitong, Chief Scientist of Shenzhen HYK Gene, chaired the meeting as director of the Alliance's Industry Committee. The attendees made in-depth exchanges and discussions around three key topics, "technology", "industry" and "capital". They were exploring a development model for gene industry which is not only suitable for national conditions of China, but also presents a chance to surpass the world's level. The conference was attended by Lv Yuyin, Secretary of Party Work Committee of Pingshan New District and leader of the preparation team of the district party committee, Yu Zhenxing, deputy director of the Frontier Biotechnology Office of Biotechnology Development Center under Ministry of Science and Technology of China, Academician Ni Jiazuan, the honorary president of the School of Life and Marine Science of Shenzhen University and Professor Yu Jun, a research fellow of Beijing Genome Research Institute under Chinese Academy of Sciences and chairman of the Council of the Alliance. They had also unveiled the plaque for the Alliance's base in Shenzhen and gave speeches.

Professor Yu Jun, a research fellow of Beijing Genome Research Institute under Chinese Academy of Sciences and chairman of the Council of the Alliance, gave a speech

Academician Ni Jiazuan, the honorary president of the School of Life and Marine Science of Shenzhen University, gave a speech

Opening ceremony for the settlement of the Alliance's Base in Shenzhen at Pingshan New District of Shenzhen

Though the gene sequencing technology had a later start in China, after years of rapid development, our technology has shortened the distance from the international level. In some aspects, our technology has even reached or even surpassed the world's level. The industrial chain has basically taken shape and the development prospect is increasingly clear. In the face of quickly changing gene technologies in the world and constraint of domestic policies and regulations, the gene industry of China is faced with double challenges from home and abroad. Under such a context, Chinese Gene Sequencing Technology and Industry Alliance have been co-established by top-class experts and scholars of the industry, senior industry insiders and several organizations and institutions. The Alliance will be committed to joining forces with strength of technology and industry such as institutes of higher learning, scientific research institutes and enterprises at home and abroad in the gene industry, a core industrial segment of the field of life health, integrating the upstream and downstream institutions of the industrial chain, changing the current situation of weak strength of independent innovative subjects; forming a collective collaboration and innovation mechanism in the field of gene, integrating industrial resources, making a full use of scientific achievements and industrial foundation to build an industrialized cluster base in cities with a favorable innovation environment.

Sheng Sitong pointed out, the Alliance is not a loose team, but a team shouldering the mission of developing gene industry of China, handling concrete affairs and serving the industry, a channel for communication between the industry and government, and a platform for exchange and mutual help of the industry. To reach this goal, the Alliance should be a good adviser and a good service provider. To be a good adviser of the government, it should provide basis and suggestions for the government at each level to make decisions on the development of gene industry and feedback the problems encountered in the development of gene industry and ask for help needed from the government. To be a good service provider, it should take advantages of the constant innovation capacity of the collective, integrate innovation elements such as core frontier technologies, talents, capital and common platforms, speed up the industrialization and marketization and surpass advanced countries of the West in the field of gene health. Simply speaking, it should offer help to each area in the development of industry such as technology, fund and talent, clear obstacles in each link of the industry and provide all-round services for the industrial development. Only in this way can the Alliance develop and become better." Finally, he expressed gratitude for the great support and help from Pingshan New District for the holding of this summit and settlement of the Alliance's Base in Pingshan and hoped that the success of the summit and settlement of the base will actively promote the development of biotechnology industry in Pingshan New District.

Dr. Sheng Sitong, Chief Scientist of Shenzhen HYK Gene Technology Co., Ltd., gave a speech

On the summit, famous experts and scholars at home and abroad such as Professor Yu Jun, Professor Sheng Sitong and Professor Zhang Mingdong, Chief Medical Officer of Boston Scientific Corporation have respectively made wonderful reports and speeches on the areas such as development of Chinese precision medicine under bio-medical innovation, the path of precision medicine industry with Chinese characteristics and researches of DNA sequencing technology.

Professor Zhang Mingdong pointed out that in the expenditure of China in medical treatment and health, the expenditure of medical apparatus is only 1/4 to 1/3 that of drugs, while in developed countries this ratio nears 1:1. This indicates that in the future the medical apparatus industry will develop faster and enjoy a brighter future in China. At present, to encourage the innovation of medical apparatus industry, each state has issued corresponding regulations to support registration of supports. Meanwhile, Zhang also shared his views on the reviewing and appraisal of FDA and CFDA innovative apparatus.

Professor Zhang Mingdong, Chief Medical Officer of Greater China Region of Boston Scientific Corporation, gave a speech

In the industry forum in the afternoon section of the afternoon, dozens of excellent representatives of the industry such as Guo Dongliang, president of Singapore Vishuo Medicine Co., Ltd., Professor Xiang Guobing, Chief Scientist of Bohai Gene, Professor Liang Junbin of Annoroad Gene Technology Limited had made wonderful sharing and discussions on topics such as new deployment of sequencing technology and industrial chain, semi-conductor gene sequencing, implementation and trend of big data in the field of precision medicine.

Ren Lufeng, Secretary General of the Alliance, pointed out in his report that the new generation gene sequencing technology has been in the market for ten years, which has opened up a new era in analysis, identification, guiding of many basic scientific issues and practical applications of life science and medicine. However, its industrial deployment has still failed to bring forth sufficient innovation capacity and achievements in the gene sequencing industry of China for years. It has become the present focus of researches how to make up a series of shortages for the development of Chinese gene sequencing industry and build an industrial deployment suitable for the rapid and innovative development of the industry in China.

The investment summit forum held during the summit was an extremely attractive link, which made the attending guests feel the wonderful sparks of thoughts at the site. Sheng Sitong, president of HYK Gene, chaired the forum; together with other big investors such as Xie Gang of Lianhe Haijie Investment; Wang Dongxiang, a partner of Qinghua Controlled Cornerstone Funds, Fang Yu, a partner of Bencao Capital, Zhou Jun of Junlian Capital and Qiu Yumin, a partner of Shangcheng Capital, they made an in-depth discussion and exchange on related topics of the hot investment issues and trend of the industry at present, staging a wonderful themed dialogue for the summit.

Investment forum of the summit

This summit has built up a very good platform for communication and exchange among experts and scholars, industrial insiders and financial investors, which has further strengthened exchange and interaction among domestic enterprises of sequencing technology, enhanced the cohesive dynamic force for China to achieve independent innovation and a leap in the field of gene sequencing. It is set to effectively promote China's gene sequencing industry to develop healthily and rapidly.